Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2236-2251

  D'Costa, Zarina J ^a   Leong, Cheng Mee ^a   Shields, Justin ^a   Matthews, Charles ^a   Hibma, Merilyn H ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Doxorubicin; E cadherin; HPV. 5 Aza 2' deoxycytidine; Indole 3 carbinol; Tamoxifen

Indexed keywords

3 INDOLEMETHANOL; 5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; PROTEIN E6; TAMOXIFEN; UVOMORULIN;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE EVASION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIVIRAL AGENTS; AZACITIDINE; CADHERINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; DOXORUBICIN; HCT116 CELLS; HUMANS; INDOLES; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TAMOXIFEN;

EID: 84875502186     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9803-0     Document Type: Article

References (78)

1. Villa LL (2011) HPV prophylactic vaccination: the first years and what to expect from now. Cancer Lett 305(2):106-112. doi:10.1016/j.canlet.2010.12.002
2. Saslow D, Wheeler CM (2007) Human papillomavirus vaccines: who will pay, who will receive, when to administer? Ethn Dis 17(2 Suppl 2):S2-8-13
3. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24 Suppl 3:S3/11-25. doi:10.1016/j.vaccine.2006.05.111
4. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC (2009) A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15(1):361-367. doi:10.1158/1078-0432.CCR-08-1725
5. Ault KA (2007) Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 107(2 Suppl 1):S31-33
6. Stanley M (2003) Immune intervention in HPV infections: current progress and future developments. Expert Rev Vaccines 2(5):615-617. doi:10.1586/14760584. 2.5.615
7. Soutter WP (1997) A comparison of cryocauterisation, laser vaporisation and large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology 17 (4):419; author reply 419. doi:10.1080/01443619750113078
8. Greenfield I, Cuthill S (2001) Antivirals. Human papillomaviruses Clinical and scientific advances (eds JC Sterling and SK Tyring):120, Äì130
9. Wierrani F, Kubin A, Jindra R, Henry M, Gharehbaghi K, Grin W, Soltz-Szotz J, Alth G, Grunberger W (1999) 5-aminolevulinic acid-mediated photodynamic therapy of intraepithelial neoplasia and human papillomavirus of the uterine cervix-a new experimental approach. Cancer Detect Prev 23(4):351-355
10. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196-200. doi:10.1038/ni758
11. Slade HB (1998) Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. European journal of dermatology: EJD 8 (7 Suppl):13-16; discussion 20-12
12. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ (2008) Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 358(14):1465-1473. doi:10.1056/NEJMoa072685
13. Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, Kitchener HC (2008) Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res 14(16):5292-5299. doi:10.1158/1078-0432.CCR-07-4760
14. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intra-epithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6(9):3406-3416
15. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR (2002) Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45(4):502-507
16. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H (2002) Safety and immuno-genicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8(12):3676-3685
17. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vul-var intraepithelial neoplasia. N Engl J Med 361(19):1838-1847. doi:10.1056/NEJMoa0810097
18. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papilloma-virus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14 (1):178-187. doi:10.1158/1078-0432.CCR-07-1880
19. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727-735
20. Tang A, Amagai M, Granger LG, Stanley JR, Udey MC (1993) Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 361(6407):82-85. doi:10.1038/361082a0
21. Matthews K, Leong CM, Baxter L, Inglis E, Yun K, Backstrom BT, Doorbar J, Hibma M (2003) Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 77(15):8378-8385
22. Boukamp P, Popp S, Bleuel K, Tomakidi E, Burkle A, Fusenig NE (1999) Tumorigenic conversion of immortal human skin keratino-cytes (HaCaT) by elevated temperature. Oncogene 18(41):5638-5645. doi:10.1038/sj.onc.1202934
23. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41(5):1751-1756
24. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M (1999) Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 5(4):937-941
25. Liu J, Lian Z, Han S, Waye MMY, Wang H, Wu MC, Wu K, Ding J, Arbuthnot P, Kew M (2005) Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 25(7):1008-1017
26. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V (1994) Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 54(17):4607-4609
27. Ravizza R, Gariboldi MB, Passarelli L, Monti E (2004) Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer 4:92. doi:10.1186/1471-2407-4-92
28. Leong CM, Hibma MH (2005) A flow cytometry-based assay for the measurement of protein regulation of E-cadherin-mediated adhesion. J Immunol Methods 302(1-2):116-124. doi:10.1016/j. jim.2005.05.001
29. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF (2006) High-throughput real-time quantitative reverse transcription PCR. Current protocols in molecular biology/edited by Frederick M Ausubel [et al] Chapter 15:Unit 15 18. doi:10.1002/0471142727.mb1508s73
30. Mueller S, Cadenas E, Schonthal AH (2000) p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res 60(1):156-163
31. Saitoh M, Shirakihara T, Miyazono K (2009) Regulation of the stability of cell surface E-cadherin by the proteasome. Biochem Biophys Res Commun 381(4):560-565. doi:10.1016/j. bbrc.2009.02.098
32. Roger L, Jullien L, Gire V, Roux P (2010) Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci 123(Pt 8):1295-1305. doi:10.1242/jcs.061002
33. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7):894-907. doi:10.1101/gad.1640608
34. Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, Scherf U, Shankavaram UT, Ziegler MS, Stewart C, Kouros-Mehr H, Cui H, Dolginow D, Scudiero DA, Pommier YG, Munroe DJ, Feinberg AP, Weinstein JN (2007) Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 6(2):391-403. doi:10.1158/1535-7163.MCT-06-0609
35. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92(16):7416-7419
36. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN (2001) Immu-nological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 61 (1):192-196
37. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55(22):5195-5199
38. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26(1):16-17. doi:10.1038/79120
39. Chang HW, Chow V, Lam KY, Wei WI, Yuen A (2002) Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 94 (2):386-392. doi:10.1002/cncr.10211
40. Chen CL, Liu SS, Ip SM, Wong LC, Ng TY, Ngan HY (2003) E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer 39(4):517-523
41. Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43 (8):3493-3496
42. Laurson J, Khan S, Chung R, Cross K, Raj K (2010) Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31(5):918-926. doi:10.1093/carcin/bgq027
43. Malanchi I, Accardi R, Diehl F, Smet A, Androphy E, Hoheisel J, Tommasino M (2004) Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J Virol 78(24):13769-13778. doi:10.1128/JVI.78.24.13769-13778.2004
44. Fan X, Liu Y, Chen JJ (2005) Down-regulation of p21 contributes to apoptosis induced by HPV E6 in human mammary epithelial cells. Apoptosis 10(1):63-73. doi:10.1007/s10495-005-6062-y
45. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH (2001) Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20 (23):2927-2936. doi:10.1038/sj.onc.1204365
46. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL (1998) Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273(7):3838-3847
47. Brew CT, Aronchik I, Hsu JC, Sheen JH, Dickson RB, Bjeldanes LF, Firestone GL (2006) Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer 118(4):857-868. doi:10.1002/ijc.21445
48. Meng Q, Goldberg ID, Rosen EM, Fan S (2000) Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat 63 (2):147-152
49. Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL, Auborn K (1999) Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 19(3A):1673-1680
50. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J, Lee AV (2003) Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res 63(17):5203-5208
51. Janakiram NB, Steele VE, Rao CV (2009) Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prevention Research 2(1):52-59. doi:10.1158/1940-6207.CAPR-08-0140
52. Cersosimo RJ (2003) Tamoxifen for prevention of breast cancer. Ann Pharmacother 37(2):268-273
53. Momparler RL, Ayoub J (2001) Potential of 5-aza-2'-deoxycyti-dine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S111-115
54. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA (1995) Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55(20):4531-4535
55. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL (2008) Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 8:128. doi:10.1186/1471-2407-8-128
56. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza-2'-deoxy-cytidine by zebularine on L1210 leukemia. Anticancer Drugs 16 (3):301-308
57. Braakhuis BJ, van Dongen GA, van Walsum M, Leyva A, Snow GB (1988) Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected]. Invest New Drugs 6(4):299-304
58. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635-1640. doi:10.1182/blood-2003-03-0687
59. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522-528. doi:10.1002/cncr.11543
60. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (8):1794-1803. doi:10.1002/cncr.21792
61. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2'-deoxycytidine, a DNA hypo-methylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18(5):956-962
62. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF (1981) Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res 5(6):453-462
63. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375. doi:10.1146/annurev. bi.58.070189.002031
64. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (6):1129-1136
65. Shah R, El-Deiry WS (2004) p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biol Ther 3(9):871-875
66. Yang SZ, Kohno N, Kondo K, Yokoyama A, Hamada H, Hiwada K, Miyake M (1999) Adriamycin activates E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Int J Oncol 15 (6):1109-1115
67. Nagafuchi A, Takeichi M (1989) Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1(1):37-44
68. Ozawa M, Ringwald M, Kemler R (1990) Uvomorulin-catenin complex formation is regulated by a specific domain in the cyto-plasmic region of the cell adhesion molecule. Proc Natl Acad Sci USA 87(11):4246-4250
69. Nagafuchi A, Ishihara S, Tsukita S (1994) The roles of catenins in the cadherin-mediated cell adhesion: functional analysis of E-cadherin-alpha catenin fusion molecules. J Cell Biol 127(1):235-245
70. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL (1998) Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngology-head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck. Surgery 118(6):810-815
71. Jin L, Qi M, Chen DZ, Anderson A, Yang GY, Arbeit JM, Auborn KJ (1999) Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res 59(16):3991-3997
72. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA, Mathis JM (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78 (2):123-129. doi:10.1006/gyno.2000.5847
73. Michnovicz JJ, Bradlow HL (1990) Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 82(11):947-949
74. Howie H, Katzenellenbogen R, Galloway D (2009) Papillomavirus E6 proteins. Virology 384(2):324-334
75. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA (2008) E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82(21):10408
76. Caberg JH, Hubert PM, Begon DY, Herfs MF, Roncarati PJ, Boniver JJ, Delvenne PO (2008) Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratino-cytes. Carcinogenesis 29(7):1441-1447. doi:10.1093/carcin/bgn145
77. Yang Z, Zhang H, Kumar R (2005) Regulation of E-cadherin. Breast Canc Online 8(03)
78. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173-185